ORAMED PHARMACEUTICALS INC.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
ORMP$3.97-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Income
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
| Nine months ended · Three months ended | |||||
|---|---|---|---|---|---|
| September 30, · September 30, · September 30, · September 30, | |||||
| 2025 · 2024 · 2025 · 2024 | |||||
| REVENUES | $2,000 | - | $ | - | - |
| COST OF REVENUE | (1,987) | - | - | - | |
| GROSS PROFIT | 13 | - | - | - | |
| RESEARCH AND DEVELOPMENT EXPENSES | (4,393) | (4,863) | (1,153) | (2,242) | |
| GENERAL AND ADMINISTRATIVE EXPENSES | (5,036) | (4,323) | (1,274) | (847) | |
| OPERATING LOSS | (9,416) | (9,186) | (2,427) | (3,089) | |
| OTHER INCOME, NET | 665 | - | 408 | - | |
| FINANCIAL INCOME (LOSS), NET | 74,278 | 3,902 | 61,470 | (15,420) | |
| INTEREST EXPENSES | - | (853) | - | - | |
| INCOME (LOSS) BEFORE TAX EXPENSES | $65,527 | (6,137) | $59,451 | (18,509) | |
| TAX EXPENSES | (11,520) | (2,767) | (11,062) | (1,133) | |
| NET INCOME (LOSS) | $54,007 | (8,904) | $48,389 | (19,642) | |
| NET INCOME (LOSS) ATTRIBUTABLE TO: | |||||
| NON-CONTROLLING INTERESTS | (34) | (33) | (6) | (23) | |
| COMPANY’S STOCKHOLDERS | 54,041 | (8,871) | 48,395 | (19,619) | |
| BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK | $1.30 | $(0.22) | $1.16 | $(0.48) | |
| DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK | $1.26 | $(0.22) | $1.13 | $(0.48) | |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME PER SHARE OF COMMON STOCK | 41,569,359 | 40,882,110 | 41,756,301 | 40,896,845 | |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME PER SHARE OF COMMON STOCK | 42,969,519 | 40,882,110 | 42,774,504 | 40,896,845 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.